

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE

P. Sonneveld¹, Ph. Moreau², H. Einsele³, H. Quach⁴, P.J. Ho⁵, M. Beksac⁶, C. Hulin⁷, E. Antonioli⁸, X. Leleu⁹, S. Mangiacavalli¹⁰, A. Perrot¹¹, M. Cavo¹², A. Belotti¹³, A. Broijl¹, H. Pei¹⁴, A. Sitthi-Amorn¹⁵, R.L. Carson¹⁵, P. Rodríguez-Otero¹⁶, M.A. Dimopoulos¹⁷, M. Boccadoro¹⁸

¹Erasmus MC Cancer Institute, Rotterdam, The Netherlands; ²University Hospital Hôtel-Dieu, Nantes, France; ³Universitätsklinikum Würzburg, Germany; ⁴University of Melbourne, Australia; ⁵Royal Prince Alfred Hospital, Sydney, Australia; ⁶Ankara University, Turkey; ⁷Hôpital Haut Lévêque, Pessac, France; ⁸University of Florence, Italy; ⁹CHU Poitiers, France; ¹⁰University of Pavia, Italy; ¹¹Centre Hospitalier Universitaire de Toulouse, France; ¹²Bologna University, Italy; ¹³ASST Spedali Civili di Brescia, Italy; ¹⁴Johnson & Johnson, USA; ¹⁵Cancer Center Clínica Universidad de Navarra, Pamplona, Spain; ¹⁷National and Kapodistrian University of Athens, Greece; ¹⁸University of Turin, Italy

Introduction. Minimal residual disease (MRD) negativity and sustained MRD negativity are associated with longer survival and are strong prognostic clinical endpoints. PERSEUS (NCT03710603) evaluated subcutaneous Dara + VRd induction/consolidation + DR maintenance vs VRd induction/consolidation + R maintenance in TE NDMM. DVRd significantly improved progression-free survival (PFS), complete response or better rate (\geq CR), and MRD negativity rate. Nearly two-thirds of patients on DR maintenance could stop treatment after achieving sustained remission, leading to DVRd being recommended by NCCN as a preferred TE NDMM regimen. Here, we report the impact of sustained MRD negativity status on PFS in PERSEUS.

Methods. TE patients with NDMM age 18–70 years were randomized 1:1 to DVRd (DVRd induction/consolidation + DR maintenance) or VRd (VRd induction/consolidation + R maintenance). The primary endpoint was PFS; MRD negativity rate (MRD negativity 10^{-5} and \geq CR) was a key secondary endpoint. Sustained MRD negativity, assessed in the intent-to-treat population, was defined as confirmed MRD negativity \geq 12 months apart and without MRD positivity in between. Functionally high risk (FHR) was defined as disease progression \leq 18 months from treatment initiation, excluding pre-progression deaths.

Results. A total of 709 patients were assigned to DVRd

(n=355) or VRd (n=354). At 47.5-month median follow-up, \geq 12-month sustained MRD negativity rates were higher overall with DVRd (64.8%; n=230) vs VRd (29.7%; n=105); this pattern persisted across clinically relevant subgroups, including age \geq 65 years and high-risk cytogenetics. Similarly, \geq 24-month sustained MRD negativity rates were higher with DVRd (55.8%; n=198) vs VRd (22.6%; n=80). Patients with \geq 12-month sustained MRD negativity vs those without had improved 48-month PFS rates regardless of treatment arm (Table). Compared with VRd, DVRd reduced FHR rates (3.1% vs 6.8%), and rates of FHR or pre-progression deaths were lower with DVRd vs VRd (5.4% vs 11.0%) in the first 18 months.

Conclusions. In TE NDMM, nearly two-thirds of patients treated with DVRd induction/consolidation and DR maintenance achieved \geq 12-month sustained MRD negativity, associated with $>$ 95% 48-mo PFS rate. Moreover, \geq 24-month sustained MRD negativity rates with DVRd were 2.5 times as high as VRd, and FHR incidence was halved with DVRd vs VRd. Collectively, these data further support the PERSEUS regimen as standard of care for TE NDMM. © 2025 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2025 ASCO Annual Meeting. All rights reserved.

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

Table. Median and 48-month PFS rates in patients receiving DVRd and VRd with achievement of sustained (≥ 12 mo) MRD negativity

	Achieved sustained (≥ 12 mo) MRD neg (10^{-5})			Without achieving sustained (≥ 12 mo) MRD neg (10^{-5})		
	DVRd (n=230)	VRd (n=105)		DVRd (n=125)	VRd (n=249)	
Median PFS, mo (95% CI)	NE (NE-NE)	NE (NE-NE)	HR=0.83 (95% CI 0.3-2.3) P=0.7149	NE (47.9-NE)	NE (45.3-NE)	HR=0.80 (95% CI 0.6-1.2) P=0.2489
48-mo PFS rate, % (95% CI)	95.3 (91.4-97.5)	94.2 (87.6-97.4)		60.3 (48.0-70.5)	54.9 (47.7-61.4)	

Hazard ratio, HR; NE, not estimable.

Median PFS and 95% CI are from Kaplan-Meier estimates.

P-value is from unstratified log-rank test.